LifeArc CEO: UK Charity Is Cashing In Its Keytruda ‘Jackpot’ To Expand R&D Focus

 
• By Sten Stovall

The CEO of LifeArc tells Scrip why the UK-based medical research charity has decided to monetize a part of its royalty interest in Merck’s hugely successful cancer drug, Keytruda.

Gambling
LifeArc hit the jackpot co-developing Merck & Co's PD-1 inhibitor Keytruda • Source: Shutterstock

More from Deals

More from Business